Form 4: Sangamo Therapeutics Director John Markels Acquires Shares and Stock Options

Director John Markels acquired 25,000 shares of common stock and 50,000 stock options in Sangamo Therapeutics on June 4, 2024.

Summary

• On June 4, 2024, John Markels, a director of Sangamo Therapeutics, acquired 25,000 shares of common stock.
• These shares are issuable upon settlement of a restricted stock unit (RSU) grant that will fully vest on the earlier of June 4, 2025, or the day prior to the 2025 annual meeting of stockholders, contingent upon continuous service.
• Markels also acquired 50,000 stock options with an exercise price of $0.5676.
• The stock options are immediately exercisable, but unvested shares purchased under the option are subject to repurchase rights by the issuer upon cessation of continuous service.
• The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions. The acquisition of shares and options can be seen as a positive sign, but it's not a strong indicator of significant positive or negative sentiment.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future.
• The vesting schedules tied to continuous service align the director's interests with the long-term success of the company.

Risks

• The unvested shares acquired through the stock options are subject to repurchase rights if the director's continuous service ceases, which could impact the director's holdings.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, and 10% owners) of a publicly traded company buy or sell the company's securities. These filings provide transparency into insider transactions and can be used by investors to gauge management's sentiment about the company's prospects.

Comparison to Industry Standards

• Equity compensation, including stock options and restricted stock units, is a common practice in the biotechnology industry to incentivize and retain key personnel.
• Vesting schedules tied to continuous service are standard in equity compensation plans to align employee and shareholder interests.
• The specific terms of the equity grants, such as the exercise price and vesting schedule, are comparable to those offered by other biotechnology companies of similar size and stage of development.

Key Dates